Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–254 of 254 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Maximum Tolerated Dose Clear all

Conditions: Non-hodgkin Lymphoma
Interventions: MT-3724; Drug
Lead sponsor: Molecular Templates, Inc.; Industry
Eligibility: 18 Years to 101 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Whittier, California • Plantation, Florida • Chicago, Illinois + 2 more

Conditions: Multiple Myeloma
Interventions: CEP-18770; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 13
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Palo Alto, California + 10 more

Conditions: Solid Tumors
Interventions: Genz-644282 (28-day dosing schedule), Genz-644282 (21-day dosing schedule); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 4
States / cities: Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 1 more

Conditions: Metastatic Solid Tumors, Esophageal Cancer, Non-Small Cell Lung Cancer
Interventions: M1231; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Breast Neoplasm, Pancreatic Neoplasm, Lung Neoplasm, Ovarian Neoplasm, Renal Neoplasm
Interventions: TAK-165; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 4
States / cities: Scottsdale, Arizona • San Antonio, Texas

Conditions: Leukemia
Interventions: Decitabine, Idarubicin, Cytarabine, Clofarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neoplasms
Interventions: Gemcitabine, BAY80-6946, Cisplatin, NaCl, BAY80-6964 fixed dose; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: Tampa, Florida • Rochester, Minnesota • Chapel Hill, North Carolina

Conditions: Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors, PNET, NHL
Interventions: DCR-MYC; Drug
Lead sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Advanced Solid Tumor, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Interventions: Elimusertib (BAY1895344); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 14
States / cities: Duarte, California • Tampa, Florida • Atlanta, Georgia + 10 more

Conditions: Lymphoma
Interventions: BI 2536; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Omaha, Nebraska • Rochester, New York + 1 more

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: Belantamab Mafodotin, Cyclophosphamide and Dexamethasone; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Solid Tumor
Interventions: Oraxol; Drug
Lead sponsor: Athenex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: Boston, Massachusetts • Buffalo, New York • San Antonio, Texas

Conditions: Cancer of Liver
Interventions: Capecitabine (Xeloda); Drug
Lead sponsor: James A. Haley Veterans Administration Hospital; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Solid Tumors
Interventions: MP-470, amuvatinib (MP-470); Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Scottsdale, Arizona • San Antonio, Texas

Search by objective public record fields.

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)

Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors

M1231 in Participants With Solid Tumors

Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2

Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia

Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies

Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma

Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies